Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 61 to 75 of 374 results for eq-5d

  1. Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA595)

    Evidence-based recommendations on dacomitinib (Vizimpro) for untreated locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    14 August 2019
    View recommendations

    Sections for TA595

  2. Infliximab for treating moderate to severe plaque psoriasis (TA134)

    Evidence-based recommendations on infliximab for treating moderate to severe psoriasis in adults.

    Technology appraisal guidance
    Published
    23 January 2008
    View recommendations

    Sections for TA134

  3. Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA496)

    Evidence-based recommendations on ribociclib (Kisqali) as initial endocrine-based therapy for hormone-receptor positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic (secondary) breast cancer in adults.

    Technology appraisal guidance
    Published
    20 December 2017

    Sections for TA496

  4. Total hip replacement and resurfacing arthroplasty for end-stage arthritis of the hip (TA304)

    Evidence-based recommendations on artificial hips and hip resurfacing for treating end-stage arthritis of the hip in adults.

    Technology appraisal guidance
    Published
    26 February 2014
    View recommendations

    Sections for TA304

  5. Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma (TA837)

    Evidence-based recommendations on pembrolizumab (Keytruda) for the adjuvant treatment of resected stage 2B and 2C melanoma in people 12 years and over.

    Technology appraisal guidance
    Published
    26 October 2022
    View recommendations

    Sections for TA837

  6. Rozanolixizumab for treating antibody-positive generalised myasthenia gravis (TA1155)

    Evidence-based recommendations on rozanolixizumab (Rystiggo) for treating antibody-positive generalised myasthenia gravis in adults.

    Technology appraisal guidance
    Published
    20 May 2026
    View recommendations

    Sections for TA1155

  7. Elosulfase alfa for treating mucopolysaccharidosis type 4A (HST19)

    Evidence-based recommendations on elosulfase alfa (Vimizim) for treating mucopolysaccharidosis type 4A in people of all ages.

    Highly specialised technologies guidance
    Published
    20 April 2022
    View recommendations

    Sections for HST19

  8. Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (TA716)

    Evidence-based recommendations on nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency in adults.

    Technology appraisal guidance
    Published
    28 July 2021
    View recommendations

    Sections for TA716

  9. Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours (TA265)

    Evidence-based recommendations on denosumab (XGEVA) for the prevention of skeletal-related events in adults with bone metastases from solid tumours.

    Technology appraisal guidance
    Published
    24 October 2012
    View recommendations

    Sections for TA265

  10. Avelumab for treating metastatic Merkel cell carcinoma (TA517)

    Evidence-based recommendations on avelumab (Bavencio) for metastatic Merkel cell carcinoma in adults.

    Technology appraisal guidance
    Last updated
    21 April 2021
    View recommendations

    Sections for TA517

  11. Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer (TA1167)

    Evidence-based recommendations on serplulimab (Hetronifly) with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    18 June 2026

    Sections for TA1167

  12. Cost effectiveness of daycare units for treating patients with an acute painful sickle cell episode:- Are daycare units cost effective compared with emergency settings for treating patients with an acute painful sickle cell episode?

    Data should be collected using validated measure(s) of HRQoL, including EQ-5D Source guidance details Comes from guidance Sickle cell

    Research recommendation
    Published
    9 June 2015

  13. For people who have experienced suspected anaphylaxis, what is the effect on health-related quality of life of (a) referral to specialist allergy services and (b) provision of adrenaline injectors, when compared with emergency treatment alone?

    recommended that data are collected using validated measure(s) of HRQoL, including EQ-5D. Source guidance details Comes from guidance...

    Research recommendation
    Published
    26 October 2020

  14. Effect of specialist services on health-related quality of life:- For people who have experienced suspected anaphylaxis, what is the effect on health-related quality of life of (a) referral to specialist allergy services and (b) provision of adrenaline injectors, when compared with emergency treatment alone?

    recommended that data are collected using validated measure(s) of HRQoL,including EQ-5D. Source guidance details Comes from guidance...

    Research recommendation
    Published
    9 June 2015

  15. Pegunigalsidase alfa for treating Fabry disease (TA915)

    Evidence-based recommendations on pegunigalsidase alfa (Elfabrio) for Fabry disease (also known as alpha-galactosidase deficiency) in adults.

    Technology appraisal guidance
    Published
    4 October 2023
    View recommendations

    Sections for TA915